{"filings":[{"id":70683,"accession_number":"0001193125-26-221971","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2026-05-13T21:20:45+00:00","items":["8.01","9.01"],"status":"ready","headline":"vTv Therapeutics upsizes ATM program to maximum authorized shares","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Filed a prospectus supplement to increase shares offered under its at-the-market sales program to the full amount authorized.","The expanded ATM program is under the company's existing shelf registration statement on Form S-3.","Legal opinion from Dechert LLP on share legality was filed as part of the registration update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68647,"accession_number":"0001641489-26-000019","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2026-05-13T20:18:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics reports Q1 net income of $24.1M on $36.8M license revenue; CATT1 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.","Revenue of $36.8M from Newsoara license amendment; $20M upfront plus up to ~$115M milestones.","Cash $98.1M at March 31, 2026, up from $88.9M; company says funds through CATT1 topline readout.","Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes — enrollment on track for completion in Q3 2026.","R&D expenses $9.0M (vs. $2.8M) driven by CATT1 trial investment; G&A $4.6M (vs. $3.7M)."],"consensus_eps_estimate":-0.0969,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":36839000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106596,"accession_number":"0001641489-26-000012","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"vTv Therapeutics posts updated investor presentation focused on diabetes pipeline","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide deck titled 'Committed to Improving the Lives of People with Diabetes' posted for March 2026.","Presentation will be used in meetings with investors, analysts, and other parties.","Filing notes the presentation may be amended or updated via future disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106595,"accession_number":"0001641489-26-000011","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.","Cash and equivalents $88.9M at Dec 31, 2025, up from $36.7M; plus $20M non-dilutive from Newsoara in Feb 2026.","Expect to complete enrollment in Phase 3 CATT1 trial for cadisegliatin in T1D in Q3 2026.","R&D expenses rose to $17.9M in 2025 (2024: $11.5M) driven by higher cadisegliatin clinical spending.","Amended Newsoara license grants global rights to PDE4 inhibitor HPP737 for $20M upfront plus up to $115M milestones and royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106594,"accession_number":"0001641489-26-000005","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"vTv Therapeutics posts updated investor slide presentation on February 26, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company posted updated investor presentation dated February 2026 on its website.","Presentation will be used in meetings with investors, analysts, and other parties.","Presentation attached as Exhibit 99.1 to Current Report on Form 8-K filed February 26, 2026.","CEO Paul J. Sekhri signed the 8-K filing for vTv Therapeutics Inc. (Nasdaq: VTVT)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106593,"accession_number":"0001641489-26-000002","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"vTv expands HPP737 license to worldwide; Newsoara pays $20M upfront, up to $115M milestones plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment grants Newsoara global rights to PDE4 inhibitor HPP737 upon $20M upfront payment.","Up to $50M in development milestones and $65M in sales-based milestones; royalties mid-single digits.","Prior amendment became null and void in June 2025; this replaces it.","Agreement with Newsoara Biopharma Co., Ltd., a Chinese partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122928,"accession_number":"0001641489-25-000066","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"vTv Therapeutics lowers stockholder meeting quorum to 33.4%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended Section 2.8 of Second Amended and Restated By-Laws on December 19, 2025.","Quorum requirement for any stockholder meeting reduced to 33.4% from prior threshold.","Amendment effective immediately upon Board approval.","Full text of amendment filed as Exhibit 3.1 to Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122927,"accession_number":"0001641489-25-000058","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.","Cash $98.5M at Sept 30, 2025, up from $36.7M at Dec 31, 2024, after $80M private placement.","First patient randomized in Phase 3 CATT1 trial of cadisegliatin; topline data H2 2026.","U.S. patent allowed for crystalline salt forms of cadisegliatin; exclusivity through 2041.","R&D expenses $7.0M, more than double Q3 2024, due to cadisegliatin spend and milestone accrual."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139625,"accession_number":"0001641489-25-000055","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"vTv Therapeutics announces fireside chat at Morgan Stanley Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company participating in fireside chat on Sept 10, 2025 from 2:35 PM - 3:10 PM EST.","Event hosted at Morgan Stanley 23rd Annual Global Healthcare Conference.","No material financial or operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139624,"accession_number":"0001193125-25-193486","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"vTv Therapeutics raises up to $80M in private placement; initial close $65M on Sept 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raises up to $80M gross proceeds from private placement of 5,243,732 units at $15.265 per unit (or $15.255 with pre-funded warrant).","Initial close of at least $65M expected on September 3, 2025; final close within 20 days.","Each unit includes one share (or pre-funded warrant) and one common warrant exercisable at $22.71 per share.","Common warrants expire on earlier of 5th anniversary or 90 days after positive top-line data from ongoing CATT1 trial.","Company enters Registration Rights Agreement to register resale of shares and warrant shares; may incur liquidated damages if registration delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139623,"accession_number":"0001641489-25-000051","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.","Cash and cash equivalents $25.9M at June 30, 2025, down from $36.7M at December 31, 2024.","First patient randomized in Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes; topline data expected H2 2026.","Appointed Michael Tung, MD, MBA as CFO in May 2025.","USPTO allowed patent claims for crystalline salt form of cadisegliatin with term through 2041."],"consensus_eps_estimate":-0.8415,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157210,"accession_number":"0001641489-25-000038","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"vTv Therapeutics stockholders elect seven directors and ratify Ernst & Young as auditor for 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, Daniel K. Spiegelman.","Votes for director nominees ranged from 2.07M to 2.18M shares; broker non-votes of 219,013 on each.","Ratification of Ernst & Young as independent auditor: 2,400,291 For, 3,852 Against, 1,416 Abstain, 0 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157209,"accession_number":"0001641489-25-000032","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"vTv Therapeutics appoints Michael Tung as CFO; reinitiates Phase 3 T1D trial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Tung appointed EVP and CFO effective May 19, 2025; base salary $450,000, target bonus 40%.","Tung brings 20+ years finance experience; previously CFO at AdvanCell, VP at FibroGen.","Company reinitiated screening in CATT1 Phase 3 trial for cadisegliatin, oral T1D adjunct to insulin.","Employment agreement includes 45,000 stock option grant, 9-month severance, 9-month non-compete.","No prior CFO departure disclosed; appointment comes at 'critical inflection point' per CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157208,"accession_number":"0001641489-25-000030","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"vTv Therapeutics posts May 2025 investor presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on May 16, 2025 for use in investor and analyst meetings.","Slide deck highlights the company's focus on type 1 diabetes.","No new financial or clinical data were disclosed in the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157207,"accession_number":"0001641489-25-000028","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.","Cash at March 31, 2025: $31.1M, down from $36.7M at December 31, 2024.","Revenue was $0 compared to $1.0M in the prior-year period.","Phase 3 CATT1 trial for cadisegliatin shortened from 12 to 6 months; topline data expected in 2H 2026.","R&D expenses $2.8M, G&A $3.7M; operating loss of $6.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157206,"accession_number":"0001641489-25-000018","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"vTv Therapeutics appoints Barry K. Brown as interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barry K. Brown, 64, appointed interim principal financial officer effective April 11, 2025; continues as chief accounting officer.","Salary remains unchanged at $231,000 per year during the interim role.","Brown previously served as interim CFO from March to December 2022 and as controller since 2000.","Company is conducting an external search for a permanent chief financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175553,"accession_number":"0001641489-25-000016","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"vTv Therapeutics posts updated March 2025 investor presentation; specific content not available for review","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing is a Reg FD disclosure of a slide deck used for meetings with investors and analysts.","Deck titled 'Improving the Lives of Millions of People Living with Type 1 Diabetes'.","No financial results, pipeline data, or material updates can be extracted from the provided excerpt.","Full presentation content was not included in the filing text; confidence in summarizing news is low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175552,"accession_number":"0001641489-25-000013","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.","FY2024 net loss attributable to shareholders $18.5M ($3.20/share) vs $20.3M ($9.71/share) in FY2023.","Cash $36.7M at Dec 31, 2024, up from $9.4M a year earlier, boosted by private placement and ATM offering.","Appointed Martin Lafontaine as Chief Commercial Officer; he brings over 25 years of diabetes commercial experience.","R&D expenses fell to $11.5M in FY2024 from $13.6M in FY2023, due to reduced cadisegliatin costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175551,"accession_number":"0001641489-25-000010","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on vTv Therapeutics' cadisegliatin Phase 3 diabetes trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold effective March 14, 2025; CATT1 trial to resume after protocol amendment.","Protocol amendment shortens trial from 12 to 6 months; primary endpoint (hypoglycemia rates) unchanged.","Hold imposed July 26, 2024 due to chromatographic signal later found to be experimental artifact; no patients dosed.","Cadisegliatin is a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes.","Company expects shorter trial to expedite initiation of larger pivotal studies for NDA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175550,"accession_number":"0001641489-25-000005","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"vTv Therapeutics CFO Steven Tuch to resign effective March 21, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Tuch, EVP and CFO, informed company of resignation on Feb 24, 2025.","Departure is not due to any disagreement with auditors or management.","Company has begun external search for a successor; Tuch will stay through 10-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175549,"accession_number":"0001641489-25-000003","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"vTv Therapeutics posts updated investor presentation for January 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated slide presentation on its website on Jan 13, 2025.","Presentation focuses on improving lives of people with Type 1 Diabetes.","No specific financial, pipeline, or regulatory updates disclosed in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192502,"accession_number":"0001641489-24-000073","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.","Cash $41.6M at Sep 30, 2024, up from $9.4M at Dec 31, 2023, boosted by private placement and ATM.","R&D spend $3.2M (up from $2.8M) on higher indirect costs; G&A $3.3M (up from $2.5M) due to share-based and legal.","Cadisegliatin program under FDA clinical hold since July 2024; company addressing basis for hold.","No revenue in Q3 2024; YTD revenue $1.0M from prior periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192501,"accession_number":"0001641489-24-000069","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"vTv Therapeutics receives termination notice for ppar-δ license from OnKure; effective Jan 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OnKure (formerly Reneo) notified vTv LLC intent to terminate the December 2017 License Agreement for vTv's ppar-δ agonist program IP.","OnKure has decided to discontinue development of the licensed program.","Termination becomes effective January 20, 2025.","Agreement had been previously amended in December 2021.","Financial impact of the termination was not disclosed by vTv."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208972,"accession_number":"0001641489-24-000063","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.","FDA placed clinical hold on cadisegliatin T1D program in July; no patients dosed in pivotal trial.","Expanded HPP737 license with Newsoara to global license contingent on $20M upfront fee.","Cantex received Orphan Drug Designation for azeliragon in pancreatic cancer.","R&D expenses decreased to $3.4M from $4.7M; G&A increased to $3.7M from $3.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208971,"accession_number":"0001641489-24-000057","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on vTv Therapeutics' cadisegliatin Phase 3 trial for type 1 diabetes","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold based on unresolved chromatographic signal in cadisegliatin ADME study.","FDA requires a single in vitro study to characterize signal before program can resume.","No patients had been dosed in CATT1 Phase 3 trial at time of hold; no prior safety issues.","vTv is working with FDA to resolve hold and resume enrollment as quickly as possible.","Cadisegliatin is an oral glucokinase activator; over 500 subjects dosed to date with favorable safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208970,"accession_number":"0001641489-24-000054","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"vTv Therapeutics expands Newsoara license globally for $20M upfront, up to $96M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to License Agreement with Newsoara Biopharma expands original China license to global.","Newsoara to pay $20M upfront within one year; if not paid, amendment void.","Up to $41M in development milestones and $35M in sales milestones, plus mid-to-upper single-digit royalties.","vTv Therapeutics LLC (subsidiary of vTv Therapeutics Inc.) is the licensor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226805,"accession_number":"0001641489-24-000045","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"vTv Therapeutics stockholders elect seven directors and approve 2024 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At the June 11, 2024 annual meeting, stockholders elected Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard Nelson, Anne Phillips, Paul Sekhri, and Daniel Spiegelman as directors.","Stockholders approved the 2024 Equity Incentive Plan with 1,814,842 votes for, 103,928 against, and 1,925 abstentions.","Ernst & Young LLP was ratified as independent auditor for fiscal 2024 with 2,106,193 votes for, 9,580 against, and 99,191 abstentions.","All director nominees received between 1,887,098 and 1,913,689 votes for, with 294,269 broker non-votes each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226804,"accession_number":"0001641489-24-000027","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.","Net loss $4.9M ($1.17/share) vs $4.5M ($2.16/share) in Q1 2023; revenue $1.0M from milestone.","R&D spend $2.6M, down from $3.9M YoY; G&A $4.0M, up from $3.5M.","First Phase 3 cadisegliatin trial in T1D expects first patient enrollment Q2 2024, top-line data Q1 2026.","Planning two international registrational trials for cadisegliatin in T1D starting 2026; T2D Phase 2 in Middle East on track H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245763,"accession_number":"0001641489-24-000020","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"vTv Therapeutics regains Nasdaq MVLS compliance; listing continues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified vTv Therapeutics on March 25, 2024 that it regained compliance with the $35M MVLS minimum.","Common stock ticker VTVT will continue listing on the Nasdaq Capital Market.","No further deficiency actions required; prior MVLS concern resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245762,"accession_number":"0001641489-24-000014","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"vTv Therapeutics elects Anne Phillips as director; Fry and Weiner resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anne Phillips elected director effective March 13, 2024; will chair Compensation Committee and serve on Audit Committee.","John Fry and Howard Weiner resigned as directors effective upon filing of the 2023 Annual Report on March 13, 2024.","Ms. Phillips is independent under Nasdaq rules and will enter standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245761,"accession_number":"0001641489-24-000010","cik":1641489,"company_name":"vTv Therapeutics Inc.","ticker":"VTVT","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.","Cash $9.4M at Dec 31, 2023; subsequent $51M PIPE from institutional investors and JDRF T1D Fund closed Feb 28, 2024.","First Phase 3 trial of cadisegliatin for type 1 diabetes to enroll first patient in Q2 2024; top-line data expected by Q1 2026.","R&D expenses $13.6M in FY2023 (up 10% YoY); G&A expenses $11.9M (down 2% YoY).","Board reduced from 9 to 7; three new directors designated by new investors including Srinivas Akkaraju from Samsara."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":143730000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}